Stock ADVM ADVERUM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Real-time Estimate Cboe BZX
Other stock markets
 12:06:34 2024-05-02 pm EDT 		5-day change 1st Jan Change
9.66 USD -1.33% Intraday chart for Adverum Biotechnologies, Inc. +1.92% +27.13%
Apr. 30 HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target MT
Apr. 29 Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
AQ
Adverum Biotechnologies: Q4 Earnings Snapshot
AQ
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
AQ
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
AQ
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
AQ
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
AQ
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
AQ
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
AQ
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
AQ
Adverum Biotechnologies: Q3 Earnings Snapshot
AQ
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
AQ
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
AQ
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
AQ
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
AQ
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
AQ
Adverum Biotechnologies to Participate in Upcoming Investor Conferences
AQ
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
AQ
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADVM Stock
  4. News Adverum Biotechnologies, Inc.
  5. Press Releases